Stay updated with breaking news from Nnexon phase 1. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Annexon Inc. (ANNX), a clinical-stage biopharmaceutical company focused on inflammatory-related diseases, reported Wednesday positive results from the Phase 1 trial of ANX1502, its oral small molecule inhibitor of the classical complement pathway. ....